Compare QDEL & XOMAO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | QDEL | XOMAO |
|---|---|---|
| Founded | 1979 | N/A |
| Country | United States | United States |
| Employees | N/A | 13 |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | N/A |
| IPO Year | N/A | N/A |
| Metric | QDEL | XOMAO |
|---|---|---|
| Price | $28.59 | $25.53 |
| Analyst Decision | Hold | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $39.33 | N/A |
| AVG Volume (30 Days) | ★ 1.0M | N/A |
| Earning Date | 02-11-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,714,400,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.42 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $19.50 | N/A |
| 52 Week High | $49.45 | N/A |
| Indicator | QDEL | XOMAO |
|---|---|---|
| Relative Strength Index (RSI) | 55.25 | 52.92 |
| Support Level | $28.22 | $25.36 |
| Resistance Level | $29.94 | $25.63 |
| Average True Range (ATR) | 1.26 | 0.19 |
| MACD | 0.06 | 0.01 |
| Stochastic Oscillator | 54.71 | 87.49 |
QuidelOrtho Corp is engaged in the development, manufacturing and marketing of rapid diagnostic testing solutions. The company is engaged in immunoassay and molecular testing, clinical chemistry and transfusion medicine which helps clinicians and patients to make decisions across the globe. Geographically the company has its presence in North America, EMEA, China and Other countries. It generates majority if its revenue from North America.
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes. Geographically, the company operates in Switzerland, United States, Asia Pacific, Europe and Others.